{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:23:14Z","timestamp":1782915794704,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T00:00:00Z","timestamp":1495065600000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.vaccine.2016.04.049","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T15:46:18Z","timestamp":1461944778000},"page":"2762-2765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-3251","authenticated-orcid":false,"given":"Paridhi","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Spurgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell R.","family":"Bakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori T.","family":"Eccleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley P.","family":"Honnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha K.","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2016.04.049_bib0105","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2009.07.095","article-title":"Vaccines for Venezuelan equine encephalitis","volume":"27","author":"Paessler","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0110","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0264-410X(97)00192-8","article-title":"Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates","volume":"16","author":"Pratt","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0115","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1016\/j.vaccine.2008.04.044","article-title":"Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates","volume":"26","author":"Fine","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0120","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.vaccine.2003.09.041","article-title":"Environmental hazard assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526","volume":"22","author":"Rao","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0125","series-title":"The 48th annual ICAAC\/IDSA 46th annual meeting","article-title":"Safety of an attenuated Venezuelan equine encephalitis virus (VEEV) vaccine in humans","author":"Holley","year":"2008"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0130","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.vaccine.2010.11.033","article-title":"Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development","volume":"29","author":"Sharma","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jviromet.2009.11.006","article-title":"A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV)","volume":"163","author":"Fine","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jviromet.2010.11.024","article-title":"Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus","volume":"171","author":"Grund","year":"2011","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0145","doi-asserted-by":"crossref","first-page":"e104708","DOI":"10.1371\/journal.pone.0104708","article-title":"Second generation inactivated eastern equine encephalitis virus vaccine candidates protect mice against a lethal aerosol challenge","volume":"9","author":"Honnold","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0150","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0155","doi-asserted-by":"crossref","first-page":"12394","DOI":"10.1128\/JVI.79.19.12394-12400.2005","article-title":"Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope","volume":"79","author":"Raviv","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13104-015-1006-2","article-title":"Inactivation of non-enveloped virus by 1,5 iodonaphthyl azide","volume":"8","author":"Gupta","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0165","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.4161\/hv.25602","article-title":"Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4\u2032-aminomethyl-trioxsalen) is highly immunogenic in mice","volume":"9","author":"Raviprakash","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0170","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1128\/JVI.02233-07","article-title":"Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity","volume":"82","author":"Raviv","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0175","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/1743-422X-9-301","article-title":"Inactivation of Chikungunya virus by 1,5 iodonapthyl azide","volume":"9","author":"Sharma","year":"2012","journal-title":"Virol J"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2016.04.049_bib0180","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/520605","article-title":"Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent","volume":"196","author":"Warfield","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0185","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1751-1097.2011.00998.x","article-title":"Photochemical inactivation of alpha- and poxviruses","volume":"87","author":"Sagripanti","year":"2011","journal-title":"Photochem Photobiol"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0190","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.vaccine.2009.10.126","article-title":"Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB","volume":"28","author":"Martin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0195","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.1128\/JVI.01345-10","article-title":"Antibody to the E3 glycoprotein protects mice against lethal Venezuelan equine encephalitis virus infection","volume":"84","author":"Parker","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.04.049_bib0200","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.virol.2007.05.041","article-title":"Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection","volume":"367","author":"Paessler","year":"2007","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16302031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16302031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:22:02Z","timestamp":1759400522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16302031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":20,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0264410X16302031"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}